Asthma Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentec

Posted on
by

Asthma Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentec
The Key Asthma Companies in the market inlcude – GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others.

 

DelveInsight’s “Asthma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Asthma, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Asthma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Asthma Market Forecast

 

Some of the key facts of the Asthma Market Report:

  • The asthma market size in the 7MM was around ~USD 27 billion in 2024 with a significant CAGR of 1.9%, with expectations of growth throughout the forecast period from 2025 to 2034.

  • In September 2025, Areteia Therapeutics reported positive Phase III outcomes from the EXHALE-4 trial, assessing dexpramipexole as an oral add-on treatment for eosinophilic asthma, highlighting its potential to enhance patient outcomes in this severe asthma subtype.

  • In September 2025, The U.S. FDA approved a supplemental new drug application for Airsupra (albuterol/budesonide), updating its U.S. prescribing information to include new data for patients with mild asthma. According to AstraZeneca, this approval broadens Airsupra’s use as an anti-inflammatory rescue therapy for adults across all levels of asthma severity.

  • In July 2025, Asthma severity is driven by multiple inflammatory pathways, making a universal treatment approach challenging. As a result, researchers are investigating precision medicine for asthma, which focuses on identifying disease subtypes using specific biological markers (biomarkers) and customizing therapies accordingly. “Through a trial that applies precision medicine to match patients with treatments best suited to their individual profiles, we aim to replicate a strategy that has proven effective in cancer research. This platform trial design allows the simultaneous evaluation of multiple interventions in enrolled participants,” researchers explained.

  • In May 2025, AstraZeneca’s triple-combination therapy, Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate), achieved the primary endpoints in two Phase III asthma trials. The KALOS (NCT04609878) and LOGOS (NCT04609904) studies showed that Breztri significantly and clinically improved lung function compared to dual-combination ICS/LABA treatments. Both randomized, double-blind trials enrolled 4,434 patients with uncontrolled asthma to assess Breztri’s efficacy as a potential therapeutic option.

  • In February 2025, Enveda, a biotechnology firm utilizing AI to convert natural compounds into novel therapies, has announced the expansion of its lead asset, ENV-294, into a new indication: asthma. Initially developed for atopic dermatitis, this innovative treatment presents a promising approach for managing respiratory inflammatory conditions. To advance this initiative, Enveda has formed an advisory board comprising leading experts in asthma research and clinical care.

  • In September 2024, Kinaset Therapeutics revealed plans for two oral presentations and a late-breaking poster presentation at the 2024 European Respiratory Society (ERS) Congress. These presentations highlight the potential of Kinaset’s lead clinical candidate, frevecitinib (KN-002), as a treatment for patients with moderate to severe asthma and those with COPD.

  • The US asthma market was valued at around USD 21.5 billion in 2024 and is expected to grow at a CAGR of 2.1% during the forecast period, driven by rising disease awareness and the introduction of emerging therapies.

  • In 2024, the combined asthma market in the EU4 and the UK was estimated at approximately USD 4.5 billion, accounting for about 17% of the total 7MM market revenue.

  • Based on DelveInsight’s estimates, the UK represented the largest asthma market in the EU4 and UK region at approximately USD 1.7 billion in 2024, whereas Spain recorded the smallest market at around USD 460 million.

  • The asthma market in Japan was estimated at USD 910 million in 2024 and is projected to grow at a CAGR of 1.4% during the forecast period (2025–2034).

  • Projections indicate that depemokimab could reach around USD 1.7 billion in revenue across the 7MM by 2034.

  • DelveInsight estimates that in 2024, the total diagnosed prevalent asthma cases across the 7MM were approximately 57 million, with numbers projected to increase by 2034.

  • In 2024, the US represented nearly 26 million of the total diagnosed asthma cases in the 7MM, including approximately 21 million adult cases, with numbers projected to rise from 2025 to 2034.

  • In 2024, around 15.2 million females in the US were affected by asthma, notably exceeding the 10.6 million cases observed in males.

  • In 2024, severity-specific asthma cases in the US included roughly 9.3 million with intermittent asthma, about 7.4 million with mild asthma, nearly 7.1 million with moderate asthma, and around 1.9 million with severe asthma.

  • In 2024, within the EU4 and the UK, the UK recorded the highest total diagnosed prevalent asthma cases at approximately 8.4 million, while Spain reported the lowest, around 2.6 million.

  • In 2024, France had nearly 3.4 million adult asthma cases, surpassing the approximately 1.3 million cases observed in children.

  • In 2024, Japan reported an estimated 248,000 severe asthma cases linked to Type 2 inflammation, compared to around 55,000 cases classified as Non-Type 2.

  • Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others

  • Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others

  • The Asthma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Asthma pipeline products will significantly revolutionize the Asthma market dynamics.

 

Asthma Overview

Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. These symptoms often occur in response to triggers such as allergens, irritants, exercise, or respiratory infections.

 

Get a Free sample for the Asthma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/asthma-market

 

Asthma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Asthma Epidemiology Segmentation:

The Asthma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Asthma

  • Prevalent Cases of Asthma by severity

  • Gender-specific Prevalence of Asthma

  • Diagnosed Cases of Episodic and Chronic Asthma

 

Download the report to understand which factors are driving Asthma epidemiology trends @ Asthma Epidemiology Forecast

 

Asthma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Asthma market or expected to get launched during the study period. The analysis covers Asthma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Asthma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Asthma Therapies and Key Companies

  • DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals

  • TEZSPIRE (tezepelumab): Amgen/AstraZeneca

  • FASENRA (benralizumab): AstraZeneca

  • Dexpramipexole: Areteia Therapeutics

  • Depemokimab (GSK3511294): GlaxoSmithKline

  • BREZTRI AEROSPHERE (BGF; PT-010): AstraZeneca

  • GSK3511294 (Depemokimab): GlaxoSmithKline

  • Masitinib (AB07105): AB Science

  • PT010: AstraZeneca

  • Dexpramipexole Dihydrochloride: Areteia Therapeutics

  • ARS 1: ARS Pharmaceuticals, Inc.

  • MEDI3506 (tozorakimab): AstraZeneca

  • AZD1402 (PRS-060): Pieris Pharma/AstraZeneca

  • Atuliflapon (AZD5718): AstraZeneca

  • Amlitelimab: Sanofi

  • Rilzabrutinib: Sanofi

  • BOXABAN (Ifetroban): Cumberland Pharmaceuticals

  • RG6341 (GDC-6599): Genentech Research/Roche

  • CBP-201: Suzhou Connect Biopharmaceuticals

  • AVTX-002 (Quisovalimab): Avalo Therapeutics

  • MRx-4DP0004: 4D Pharma plc

  • SB010: Sterna Biologicals

 

Discover more about therapies set to grab major Asthma market share @ Asthma Treatment Landscape

 

Asthma Market Strengths

  • Robust pipeline of drugs targeting a variety of different and more effective pathogenic mechanisms in asthma.

 

Asthma Market Opportunities

  • Availability of varied formulation types and convenient dosing schedules for more effective treatment.

 

Scope of the Asthma Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others

  • Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others

  • Asthma Therapeutic Assessment: Asthma current marketed and Asthma emerging therapies

  • Asthma Market Dynamics: Asthma market drivers and Asthma market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Asthma Unmet Needs, KOL’s views, Analyst’s views, Asthma Market Access and Reimbursement

 

To know more about Asthma companies working in the treatment market, visit @ Asthma Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Asthma Market Report Introduction

2. Executive Summary for Asthma

3. SWOT analysis of Asthma

4. Asthma Patient Share (%) Overview at a Glance

5. Asthma Market Overview at a Glance

6. Asthma Disease Background and Overview

7. Asthma Epidemiology and Patient Population

8. Country-Specific Patient Population of Asthma

9. Asthma Current Treatment and Medical Practices

10. Asthma Unmet Needs

11. Asthma Emerging Therapies

12. Asthma Market Outlook

13. Country-Wise Asthma Market Analysis (2020–2034)

14. Asthma Market Access and Reimbursement of Therapies

15. Asthma Market Drivers

16. Asthma Market Barriers

17. Asthma Appendix

18. Asthma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/